ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.49 CNY | +0.87% |
|
+9.84% | -20.59% |
| Sales 2024 * | 1.16B 161M 13.4B | Sales 2025 * | 1.5B 207M 17.27B | Capitalization | 6.22B 859M 71.59B |
|---|---|---|---|---|---|
| Net income 2024 * | 387M 53.41M 4.45B | Net income 2025 * | 517M 71.35M 5.95B | EV / Sales 2024 * | 5.34 x |
| Net cash position 2024 * | - 0 0 | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | 4.14 x |
| P/E ratio 2024 * |
16
x | P/E ratio 2025 * |
12
x | Employees | 1,129 |
| Yield 2024 * |
1.81% | Yield 2025 * |
2.29% | Free-Float | 40.03% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.87% | ||
| 1 week | +9.84% | ||
| Current month | +3.25% | ||
| 1 month | +3.25% | ||
| 3 months | -5.07% | ||
| 6 months | -26.90% | ||
| Current year | -20.59% |
1 week
9.48
10.50
1 month
9.3510.84
Current year
8.0613.35
1 year
8.0617.47
3 years
8.0647.90
5 years
3.5647.90
10 years
3.0847.90
| Managers | Title | Age | Since |
|---|---|---|---|
Zhi Guo Zheng
CEO | Chief Executive Officer | 53 | 15/14/15 |
Ding Min Zhu
DFI | Director of Finance/CFO | 57 | 02/21/02 |
Hua Dong Zhang
BRD | Director/Board Member | 47 | 14/14/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Fei Chen
BRD | Director/Board Member | 44 | 08/15/08 |
Zhi Guo Zheng
CEO | Chief Executive Officer | 53 | 15/14/15 |
Zhi Shu Yang
BRD | Director/Board Member | 58 | 13/20/13 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 10.49 | +0.87% | 4,548,732 |
| 25/24/25 | 10.4 | +3.07% | 5,357,286 |
| 24/24/24 | 10.09 | +1.00% | 2,873,756 |
| 23/24/23 | 9.99 | +0.60% | 5,152,012 |
| 22/24/22 | 9.93 | +3.98% | 6,445,888 |
End-of-day quote Shanghai S.E., April 26, 2024
More quotes
Zhejiang Ausun Pharmaceutical Co., Ltd. is a China-based company principally engaged in the research and development, production and sales of specialty bulk pharmaceutical chemicals (BPCs) and pharmaceutical intermediates. The Company's main products include bimatoprost, latanoprost, latanoprostene bunod, entecavir, selectfluor and other intermediates. The Company is also involved in the provision of customized production, as well as research and development services to customers through its subsidiaries.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.49
Average target price
-
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -20.59% | 859M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- 603229 Stock
